Prosecution Insights
Last updated: November 04, 2026

Guangzhou Healthquest Pharma Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Guangzhou Healthquest Pharma Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals, assigned across 2 examiners and 2 art units. MOU, LIYUAN is the busiest examiner, with 1 pending action.

The one-to-one distribution across examiners and art units indicates that the portfolio’s current prosecution activity is not concentrated in a single examination channel. Counsel should track each matter separately and avoid assuming that developments in one application will predict treatment in another.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
§102 only1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MOU, LIYUAN 1 43.8% +59.9%
CHONG, YONG SOO 1 43.8% +41.7%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18978741 NOVEL APPLICATION OF GZD824 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN TREATING DISEASES MOU, LIYUAN —
18298800 Combination Therapies for Treating Cancer CHONG, YONG SOO —

Top Art Units

Art UnitApps
1628 1
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18978741 NOVEL APPLICATION OF GZD824 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN TREATING DISEASES MOU, LIYUAN 1628 §102Other Non-Final OA — Pending Dec 12, 2024
18298800 Combination Therapies for Treating Cancer CHONG, YONG SOO 1623 §103Other Non-Final OA — Pending Apr 11, 2023

Managing Guangzhou Healthquest Pharma Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Guangzhou Healthquest Pharma Co. Ltd. have?

Guangzhou Healthquest Pharma Co. Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Guangzhou Healthquest Pharma Co. Ltd. applications?

Liyuan Mou has the most, with 1 of Guangzhou Healthquest Pharma Co. Ltd.'s pending office actions.

What technology area are Guangzhou Healthquest Pharma Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month